MRSA

Background

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most studied antibiotic-resistant bacteria in healthcare. It is Staphylococcus aureus — a common coloniser of human skin and nasal passages and a frequent cause of skin, soft-tissue, surgical-site, bloodstream, and respiratory infections — that has acquired resistance to methicillin and the related beta-lactam antibiotics that are first-line for ordinary S. aureus. That resistance narrows the therapeutic options and, in chronic wounds and healthcare settings, drives substantial morbidity.

MRSA is also a recurring focus of Manuka honey research, for two reasons. The first is clinical relevance: chronic wounds colonised by MRSA are a real and difficult problem, and any product with measured activity against these organisms is worth evaluating. The second is mechanistic interest: Manuka honey acts on bacteria through several pathways at once, which is precisely the kind of profile that makes single-step resistance harder to evolve than against a single-target antibiotic.

This page covers what the evidence supports and where it stops. The short version: there is meaningful clinical evidence for Manuka honey dressings in MRSA-colonised wounds, and there is no evidence — and no plausible mechanism — for treating systemic MRSA infection by eating honey.

How Manuka may help

The mechanistic argument is well rehearsed elsewhere on this site, particularly on the methylglyoxal page; the MRSA-relevant version is brief.

Manuka honey's non-peroxide antibacterial activity, attributed mainly to MGO, acts on bacteria through several routes simultaneously: glycation of bacterial proteins, modifying their structure and function; disruption of membrane integrity; and interference with quorum-sensing, the chemical signalling bacteria use to coordinate biofilm formation and virulence. In laboratory work this multi-target profile inhibits both planktonic (free-floating) and biofilm-embedded MRSA, including strains resistant to multiple antibiotic classes.

The relevance to MRSA specifically is that biofilms are a major reason MRSA persists in chronic wounds, and a major reason it is hard to clear with antibiotics alone. Activity against biofilm-embedded organisms is one of the more distinctive arguments for Manuka honey dressings in wound care, and is the part of the laboratory profile that translates most directly into the clinical question.

The honest framing remains the same as elsewhere: this is a topical and laboratory mechanism. Any role in clinical care is in applied contexts — wound dressings, in clinical pathways — not in oral or systemic treatment of infection.

What the evidence shows

The clinical evidence base for Manuka honey against MRSA is concentrated in wound care. A randomised controlled trial across three New Zealand clinical sites, comparing UMF 24+ (MGO 1,122+) honey dressings against five conventional antiseptics in chronic venous leg ulcers, reported sustained bactericidal activity over 14 days. Whole-genome sequencing of paired pre- and post-treatment isolates detected no resistance-associated mutations — a methodology that is closer to what an antimicrobial-pharmacology question requires than the in-vitro studies that dominate the broader literature.

Beyond that trial, the evidence base is laboratory and observational: consistent in-vitro activity against MRSA at clinically used MGO concentrations; case series and smaller studies in clinical wound contexts reporting reductions in MRSA bioburden under Manuka honey dressings; and product registrations supporting the use of medical-grade Manuka honey in wounds where MRSA is a concern.

What the evidence does not support is language like "treats MRSA infection" in any systemic sense. The defensible claims are: in-vitro activity against MRSA across multiple clinical isolates; clinical activity against MRSA-colonised chronic wounds when used as part of a regulated medical-grade dressing; and a multi-target mechanism that makes resistance harder to evolve in laboratory and clinical conditions studied to date.

Practical use

The relevant practical guidance lives on the skin and wound care page. The short version: any wound with confirmed or suspected MRSA colonisation belongs in a clinical care pathway, with culture-directed antibiotics where indicated and regulated medical-grade Manuka honey dressings where they are appropriate. That decision belongs with the treating clinician, using the product registered for that purpose — not with retail food-grade honey from the pantry.

If a wound is showing signs of infection — spreading redness, swelling, heat, pus, fever, or red streaking — the right step is medical assessment, not a higher grade of honey. Manuka honey has a real and unusual role in the MRSA story, in a specific clinical context. The story is most accurately told when the limits of that context are stated alongside the evidence.